IMR Press / EJGO / Volume 24 / Issue 3-4 / pii/2003162

European Journal of Gynaecological Oncology (EJGO) is published by IMR Press from Volume 40 Issue 1 (2019). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on as a courtesy and upon agreement with S.O.G.

Open Access Original Research

Preoperative serum vascular endothelial growth factor (VEGF) 1n ovarian masses

Show Less
1 Department of Obstetrics and Gynecology, Osnzangazi University, Eskisehir, Turkey
2 Department of Biochemistry, Osnzangazi University, Eskisehir, Turkey
3 Faculty of Medicine, Osnzangazi University, Eskisehir, Turkey
Eur. J. Gynaecol. Oncol. 2003, 24(3-4), 271–278;
Published: 10 June 2003

Purpose of the investigation: To determine the diagnostic value of serum vascular endothelial growth factor (VEGF) in the preo­perative assessment of the nature of ovarian masses. Materials and Methods: A propective cohort study was conducted from August 2001 to September 2002 on 40 premenopausal and 23 postmenopausal patients with ovarian masses. During preoperative workup, patient age, serum Ca-l25 levels, serum VEGF levels, and tumor volume based on ultrasonographic examination were determined. Laparoscopic (n = 23) or laparotomic (n = 39) approaches were undertaken to obtain the final pathologic result. According to the final ovarian pathology, follicular cysts, corpus luteum cysts and endometriomas were grouped as non-neoplastic ovarian masses (n = 40, group I). Serous or mucinous cyctadenomas, dermoid tumors and fibromas were allocated into the neoplastic benign ovarian mass group (n = 10, group II). Primary mali­gnant ovarian neoplasms were categorized into the neoplastic-malign group (n = 12, group III). Results: Mean ages of cases among groups I, II and III were 39.0 ± 2.0, 42.2 ± 5.2 and 56.9 ± 4.2, respectively. As age of the cases enrolled in this study increased, the more likely was the occurrence of neoplastic malign ovarian pathologies (p < 0.001). Among post­menopausal cases diagnosed with an ovarian mass, serum Ca-125 levels were 113.5 ± 20 IU/ml compared to those in premenopausal cases (85.8 ± 16.0, p = 0.05). The values for serum VEGF values among pre- and postmenopausal ovarian masses were 46.2 ± 6.7 pg/ml and 68.2 ± 7.9, respectively (p = 0.04). In group 1, serum VEGF levels of endometriomas (56.5 ± 1.5 pg/ml) were higher com­pared to those of follicular or corpus luteum cysts (30.6 ± 2.8, p = 0.05). In contrast, tumor size appeared to be larger in non-endome­triotic, non-neoplastic cysts (0.01 ± 2.0 cm), compared to endometriomas (6.4 ± 0.6 cm, p < 0.01). Serum VEGF levels of group III were higher than other groups (p < 0.001). With respect to the discriminating benign or malign nature of the mass, with a specific cut­off value of serum VEGF level of 68.7 pg/ml, the sensitivity, specificity, positive and negative likelihood ratios were 92.3%, 88.0%, 3.3 and 0.1, respectively. For serum Ca-125 levels, the sensitivity, specificity, positive and negative likelihood ratio with a statistically rele­vant cut-off value of l02 IU/ml were, 76.9%, 76.0%, 3.21 and 0.3, respectively. Area under curve (AUC) for serum VEGF and Ca-125 values were 0.938 (95% CI: 0.81-0.96) and 0.769 (95% CI: 0.64-0.86), respectively (p = 0.02). Among the postmenopausal group, AUC for serum VEGF and Ca-125 was detected as 0.902 (95% CI: 0.70-0.98) and 0.873 (95% CI: 0.66-0.91) (p = 0.14). Conclusion: Serum VEGF has the potential to be considered as a tumor marker with a good diagnostic relevance in differentia­ting the nature of ovarian masses.

Vascular endothelial growth factor
Ovarian mass
Back to top